6-(3-hydroxyphenyl)-2-morpholino-4-[4-(4-nitrophenyl)piperazin-1-yl]pyrimidine | 701243-45-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-(3-hydroxyphenyl)-2-morpholino-4-[4-(4-nitrophenyl)piperazin-1-yl]pyrimidine
• 英文别名: 3-{2-morpholin-4-yl-6-[4-(4-nitrophenyl)piperazin-1-yl]pyrimidin-4-yl}phenol；3-[2-morpholin-4-yl-6-[4-(4-nitrophenyl)piperazin-1-yl]pyrimidin-4-yl]phenol
• CAS: 701243-45-0
• 化学式: C₂₄H₂₆N₆O₄
• 分子量: 462.508
• InChiKey: CBESGUVHUXXEKU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  34
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  111
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
  申请人：Butterworth Sam

  公开号：US20090233926A1

  公开（公告）日：2009-09-17

  The invention concerns pyrimidine derivatives of Formula (I), wherein each of p, R 1 , R 2 , q, R 3 , r, R 4 , X 1 and Q 1 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in a method for producing an anti-proliferative effect in a warm blooded animal such as man.

  本发明涉及公式(I)的嘧啶衍生物，其中p、R1、R2、q、R3、r、R4、X1和Q1中的每一个都具有描述中定义的任何含义；制备它们的方法，包含它们的制药组合物以及它们在制造抗增殖作用的方法中的使用，该方法用于温血动物，例如人类。
• PYRIMIDINE DERIVATIVES
  申请人：Butterworth Sam

  公开号：US20090270390A1

  公开（公告）日：2009-10-29

  The invention concerns pyrimidine derivatives of Formula (I) wherein each of p, R 1 , R 2 , q, R 3 , r, R 4 , X 1 and Q 1 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in a method for producing an anti-proliferative effect in a warm blooded animal such as man.

  本发明涉及式（I）的嘧啶衍生物，其中p、R1、R2、q、R3、r、R4、X1和Q1的每个含义均与描述中定义的任何含义相同；它们的制备过程，含有它们的制药组合物以及它们在制造抗增殖效应的方法中在温血动物（如人）中的使用。
• 2-BENZIMIDAZOLYL-6-MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
  申请人：Butterworth Sam

  公开号：US20100022534A1

  公开（公告）日：2010-01-28

  The invention concerns pyrimidine derivatives of Formula (I) wherein each of p, R 1 , R 2, q, R 3 , r, R 4 , s, t, X 1 and Q 1 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in a method for producing an anti-proliferative effect in a warm blooded animal such as man.

  本发明涉及式（I）的嘧啶衍生物，其中p，R1，R2，q，R3，r，R4，s，t，X1和Q1中的每一个都具有描述中定义的任何含义；它们的制备方法，含有它们的制药组合物以及它们在制造抗增殖效应的方法中的用途，该方法适用于温血动物，例如人类。
• SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE
  申请人：Nuss John N.

  公开号：US20090060912A1

  公开（公告）日：2009-03-05

  Compounds having formula I are provided where the variables have the values described herein. Pharmaceutical formulations include the compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and combinations with other agents. A method of treating a patient comprises administering a pharmaceutical formulation according to the invention to a patient in need thereof.

  提供了化学式I的化合物，其中变量具有所述的值。药物制剂包括该化合物或其药学上可接受的盐以及药学上可接受的载体和其他药物的组合。治疗患者的方法包括向需要该制剂的患者给予本发明的药物制剂。
• 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
  申请人：Novartis AG

  公开号：EP2316831A1

  公开（公告）日：2011-05-04

  Compounds having formula I are provided where the variables have the values described herein. Pharmaceutical formulations include the compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and combinations with other agents. These compounds are phosphotidylinositol 3-kinase (PI3K) inhibitors.

  提供了具有式 I 的化合物，其中的变量具有本文所述的值。 药物制剂包括这些化合物或其药学上可接受的盐和药学上可接受的载体以及与其他制剂的组合。这些化合物是磷脂酰肌醇 3- 激酶（PI3K）抑制剂。